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Abstract
Chemotherapy is a primary treatment for cancer, but its efficacy is often limited by the adverse effects of cytotoxic agents.
Targeted drug delivery may reduce the non-specific toxicity of chemotherapy by selectively directing anticancer drugs to
tumor cells. MUC1 protein is an attractive target for tumor-specific drug delivery owning to its overexpression in most
adenocarcinomas. In this study, a novel MUC1 aptamer is exploited as the targeting ligand for carrying doxorubicin (Dox) to
cancer cells. We developed an 86-base DNA aptamer (MA3) that bound to a peptide epitope of MUC1 with a Kd of 38.3 nM
and minimal cross reactivity to albumin. Using A549 lung cancer and MCF-7 breast cancer cells as MUC1-expressing models,
MA3 was found to preferentially bind to MUC1-positive but not MUC1-negative cells. An aptamer-doxorubicin complex
(Apt-Dox) was formulated by intercalating doxorubicin into the DNA structure of MA3. Apt-Dox was found capable of
carrying doxorubicin into MUC1-positive tumor cells, while significantly reducing the drug intake by MUC1-negative cells.
Moreover, Apt-Dox retained the efficacy of doxorubicin against MUC1-positive tumor cells, but lowered the toxicity to
MUC1-negative cells (P,0.01). The results suggest that the MUC1 aptamer may have potential utility as a targeting ligand
for selective delivery of cytotoxic agent to MUC1-expressing tumors.
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Introduction
Chemotherapy is an essential treatment for cancer, especially
for late-stage metastatic disease. However, the efficacy of
chemotherapy is often limited by the adverse effects of cytotoxic
agents that are employed in most therapeutic regimens. A major
problem associated with cytotoxic drugs is that they cause
damages to both cancer cells and normal tissue, generating
serious adverse effects that often limit the intensity and the
duration of chemotherapy. Consequently, it is frequently difficult
for cytotoxic drugs to eliminate all cancer cells within the body,
resulting in treatment failure and poor prognosis. Such failure
underscores the need to develop increasingly potent therapy with
reduced toxicity. One approach to achieve the goal is targeted
cancer therapy, in which anticancer drugs are selectively delivered
to cancer cells, so that the cytotoxicity against tumor is enhanced
while the adverse effects reduced. Targeted cancer therapy holds
promise in improving anticancer efficacy. It has been reported that
aptamer-guided carriers containing paclitaxel can significantly
improve the efficacy against prostate cancer in animal models [1].
Monoclonal antibodies have also been covalently linked to drugs
for targeted cancer therapy [2]. A study of trastuzumab emtansine
(T-DM1), a conjugate of the humanized anti-HER2 antibody and
a chemical drug, is currently in phase III clinical trial [3].
A typical targeted drug delivery system usually consists of an
anticancer drug and a targeting ligand, which can specifically
binds to tumor markers that abundantly express in cancer cells [4].
An ideal tumor marker for targeted therapy should be a
membrane protein that is overexpressed on the surface of cancer
cells, with relatively low expression in normal tissue. MUC1 is a
well-characterized large transmembrane glycoprotein that may
potentially serve as the target for anticancer therapy. Its expression
is increased by at least 10-fold in most malignant adenocarcino-
mas, including breast cancer, lung cancer, and colon cancer,
making it an attractive tumor marker for targeted therapy [5].
Besides the tumor marker, the tumor-targeting ligand is also an
important element for targeted cancer therapy. An ideal targeting
ligand should have high binding affinity for the tumor marker,
with good specificity and low immunogenicity [6]. Lately, novel
targeting agents, including aptamers [7], short peptides [8] and
other small molecules [9], have become the new generation
targeting molecules. Aptamers are single-strand oligonucleotides
that can bind to target molecules with high affinity and specificity.
Comparing to monoclonal antibodies, aptamers possess distinctive
advantages as targeting ligand: high affinity for binding to most
molecules, limited synthesis cost, low-immunogenicity, and small
size that allows it to penetrate solid tumors [10]. Due to these
advantages, aptamers have been employed as novel targeting
ligands in drug delivery systems against prostate cancer [11,12,13]
and leukemia [14]. For the tumor marker of MUC1, Ferreira et al
have developed several aptamers that could bind to the MUC1-
positive tumor cells [15]. It has also been shown that the MUC1
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31970aptamers could be employed to selectively deliver phototherapy
agent to cancer cells in vitro [16].
Cytotoxic drugs are the major components of most chemother-
apy regimens for cancer treatment. It is therefore important to
explore whether MUC1 aptamer can be used directly to selectively
deliver cytotoxic agent to cancer cells. So far, however, no such
study has been reported in literature. Here in this study, we
developed a novel MUC1 aptamer, and evaluated its capacity for
delivering doxorubicin to cancer cells in vitro. Specifically, we
selected an 86-base DNA aptamer (termed MA3) against a peptide
epitope of MUC1, and evaluated its binding affinity to MUC1-
positive and -negative cells. To explore the binding specificity of
the aptamer, we also evaluated its binding to albumin, which is the
most abundant protein in plasma, and may non-specifically bind
to aptamers and interfere with their targeting function. Doxoru-
bicin is one of the most widely used anticancer drugs, and can
inhibit the proliferation of cancer cells through intercalating into
the DNA structure in cell nuclei. An aptamer-doxorubicin
complex (Apt-Dox) was formulated by incorporating doxorubicin
into the aptamer structure of MA3. We now report that Apt-Dox
can selectively deliver doxorubicin to MUC1-positive cells in vitro.
Materials and Methods
Reagents
Oligonucleotide primers were synthesized by Invitrogen
(Shanghai China). Peptides of at least 95% purity were synthesized
by SBS Genetech (Beijing China). Bovine serum albumin (BSA)
was purchased from Tbdscience (Tianjin China). Monodispersed
magnetic urea-formaldehyde microspheres were purchased from
Baseline Chromtech (Tianjin China). Trypsin was purchased from
Amresco (US). Streptavidin-coated magnetic beads were pur-
chased from Promega (US). 1-Ethyl-3-(3-dimethyllaminopropyl)-
carbodiimide hydrochloride (EDC) was purchased from Sigma
(US).
Cell lines
Human breast cancer (MCF-7), human liver cancer (HepG2),
human lung cancer (A549), and human normal liver cells (L02)
were obtained from the Cell Center of Chinese Academy of
Medical Sciences (Beijing, China). Cells were cultured in DMEM
medium supplemented with 10% fetal bovine serum (FBS) and a
mixture of penicillin/streptomycin. Cells were grown at 37uCi na
humidified atmosphere with 5% of CO2. All experiments were
performed on cells in the exponential growth phase.
Immobilization of target on magnetic beads
The target for aptamer selection is a 9-AA peptides (peptide1)
with the sequence of APDTRPAPG. The conjugation of the target
to magnetic beads was accomplished via cross-linking of 2COOH
and 2NH2. Two mg of peptide1 was mixed with 5610‘5
carboxylated magnetic beads, and incubated with 200 ml EDC
(40 mM) at room temperature with gentle stirring for 2 h. The
magnetic beads were then washed for three times with Hanks
buffer, and stored at 4uC. Similar method was employed to
conjugate the beads with other substances, including BSA and a
29-AA long peptides with the sequence of GSTAPPAGHGVT-
SAPDTRPAPGPGSTAPP (peptide2).
SELEX library and primers
A starting DNA library consisting of 86-mer oligonucleotides
with central 40-base long randomized sequences was synthesized.
The sequence of library is 59AACCGCCCAAATCCCTAA-
GAGTC-N40-CACAGACACACTACACACGCACA39, where
N represents a randomized nucleotide of either A, G, C or T.
An FITC-labeled 59 primer (59-FITC-AACCGCCCAAATCCC-
TAAGAGTC-39) and a biotin-labeled 39 primer (59-B-TGTG-
CGTGTGTAGTGTGTCTGTG-39) were used in the PCR for
the synthesis of double-labeled, double-stranded DNA molecules,
which was then mixed with streptavidin-coated magnetic beads for
10 min at room temperature. After denaturing in alkaline
condition (0.1 M NaOH), the FITC-conjugated sense single-
strand DNA (ssDNA) was separated from the biotin-labeled
antisense ssDNA strand with streptavidin-coated magnetic beads
and used for aptamer selection.
In vitro selection of target-binding aptamers
The procedures of selection were as follows. The ssDNA pool
(200 pmol) was first heated at 95uC for 5 min and then cooled
immediately to 0uC in binding buffer (Hanks buffer) for 15 min
before binding to target. To reduce background interference,
0.1 mg/ml salmon sperm DNA and 1 mg/ml of BSA were added
to the binding buffer. In the initial selection round, the peptide1-
coated beads were suspended in 200 ml of binding buffer
containing 200 pmol of random ssDNA. After incubating the
mixture at 37uC for 30 min with gentle shaking, the unbound
oligonucleotides were removed by washing four times with 500 ml
of binding buffer. Subsequently, bead-bound oligonucleotides
mixtures were amplified by PCR with FITC- or biotin-labeled
primers (25 cycles of 40 sec at 94uC, 30 sec at 65uC, 40 sec at
72uC, followed by 10 min at 72uC, the Taq polymerase and
dNTPs were obtained from Takara). The ensuing dsDNA from
PCR was separated into ssDNA via procedure described above.
The selected sense ssDNA separated from the biotinylated
antisense DNA strand by streptavidin-coated magnetic beads
was used for the next round of SELEX. After several rounds of
selection, the selected ssDNA pool was PCR-amplified using
unmodified primers and cloned into Escherichia Coli with the TA
cloning kit for DNA sequencing.
Flow cytometry analysis
To monitor the enrichment of aptamer candidates after
selection, the FITC-labeled ssDNA pool was incubated with
peptide1-coated magnetic beads in 200 ml of selection buffer
containing 10% FBS at 37uC for 30 min. The beads were washed
twice with 0.5 ml of binding buffer and then suspended in 0.2 ml
of binding buffer. The FITC fluorescence was determined with a
FACScalibur cytometer (Accuri C6, US). The FITC-labeled
randomized ssDNA library was used to generate the control signal.
The binding affinity of aptamers was determined by incubating
peptide1-coated magnetic beads with varying concentrations of
FITC-labeled aptamer in 200 ml of binding buffer at 37uC for
30 min. The beads were washed twice with 0.5 ml of binding
buffer, suspended in 0.2 ml of binding buffer, and subjected to
flow-cytometric analysis. The FITC-labeled unselected ssDNA
library was used as a negative control to determine nonspecific
binding. All of the experiments for binding assay were repeated
three times. The mean fluorescence intensity of target labeled by
aptamers was used to calculate for specific binding by subtracting
the mean fluorescence intensity of nonspecific binding from
unselected library DNA [17]. The equilibrium dissociation
constants (Kd) of the aptamer–peptide1 interaction were obtained
by fitting the dependence of fluorescence intensity of specific
binding on the concentration of the aptamers to the equation
Y=B max X/(Kd+X).
To evaluate the specific binding of aptamers to target, the
FITC-labeled aptamer was separately incubated with peptide1-,
peptied2-, or BSA-coated magnetic beads. The beads were washed
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binding buffer, and analyzed by flow cytometry. For assessing
aptamer binding to cells, cells were scraped off the culture bottle
and washed with Hanks buffer. The FITC-labeled aptamer was
incubated with 10‘5 of either MCF-7, A549, HepG2 or L02 cells
in binding buffer at 37uC for 30 min. Cells were then washed
thrice with Hanks buffer and analyzed with flow cytometrey.
Cells and siRNA transfection
A549 cells were plated in 6-well plates at 1–3610
5cells/well,
grown in antibiotic-free media overnight, and transfected with
MUC1 siRNA or control siRNA [18] using Lipofectamine 2000 in
Opti-MEM I reduced serum medium according to the manufac-
turer’s instructions (Invitrogen Life Technology, Inc.). After
72 hours, cells were harvested and stained with FITC labeled
aptamer for flow cytometry assay, and cell lysates were prepared
for immunoblot analysis.
Western blot analysis
Lysates were prepared from subconfluent cells. Equal amounts
of protein were separated by SDS-PAGE and transferred to
nitrocellulose membranes. The immunoblots were probed with
anti-MUC1 antibody. The immunocomplexes were detected with
horseradish peroxidase-conjugated secondary antibodies and
enhanced chemiluminescence (ECL).
Loading of aptamer with doxorubicin
Aptamers were first heated at 95uC for 5 min and then cooled
immediately to 0uC in water for 15 min. The aptamers were
incubated in an aqueous solution of doxorubicin (3 nM) for 1 h in
a black 96-well plate at various aptamer/dox molar ratios. The
fluorescence spectrum of doxorubicin was then examined by a
Synergy4 analyzer (lEx=488 nm, lEm=500–700 nm). FITC-
labeled Apt-Dox or Apt-Dox were incubated with A549 cells in
binding buffer at 37uC for 30 min. Cells were then washed thrice
with Hanks buffer and analyzed with flow cytometrey.
Cellular uptake of doxorubicin
The specific cellular uptake of Apt-Dox by MUC1-positive
A549 cell was studied by confocal fluorescence scanning
microscopy (Perkin Elmer Ultraview, US) and flow cytometry.
HepG2 cell was used as a MUC1-negative control. Cells were
allowed to adhere to a glass cover slip for 24 h. The cells were then
incubated with 1.5 mM of Dox or Aptamer-Dox for 2 h at 37uC.
After being washed twice with Hanks buffer, the cells were fixed
with 4% formaldehyde for 10 min and analyzed by confocal
fluorescence scanning microscopy.
For flow cytometry analysis, cells were scraped off from the
culture bottle and washed twice with Hanks buffer. The cells were
incubated with 1.5 mM Dox or Aptamer-Dox for 4 h at 37uC,
and washed twice with Hanks buffer. The cells were then fixed
with 4% formaldehyde for 10 min and analyzed with flow
cytometriy.
MTS cell viability assay
To evaluate the cytotoxicity of Apt-Dox or Dox against A549
and HepG2 cells, both cell lines were first grown in 96-well plates,
and then co-incubated at 37uC with Apt-Dox, Dox, or aptamer at
the concentration of 3 mM for 4 h. The cells were washed with
Hanks buffer for two times, and cultured for a further 48 h.
Afterwards, MTS assay (Promega, US) was used to determine the
cell viability per standard protocol outlined by the manufacture.
Statistics
Statistical analysis was performed using Statistical Analysis
System (SAS, Version 9.2). One-way ANOVA with Fisher’s least
significant difference (LSD) post hoc comparisons at 99%
confidence interval was used for statistical comparisons. All data
are presented as a mean value with its standard deviation indicated
(mean 6 SD).
Results
Aptamer selection and characterization
The extracellular protein core of MUC1 is made up of variable
number of a highly conserved tandem repeat sequence composed
of 20 amino acids (TAPPAGHGVTSAPDTRPAPGPGS) [19].
Among the tandem repeat, the sequence APDTRPAPG had been
identified as the most immunodominant peptide epitope [20], and
was used as the target for MUC1 aptamer selection in prior
research [15]. Here in this study, we also used this peptides as the
target in our SELEX process. The target peptides were covalently
conjugated to magnetic beads using EDC as the catalyst. During
each round of selection, the beads were incubated with FITC-
labeled ssDNA pool, and the enrichment of aptamers was
monitored by flow cytometry. Compared with the random DNA
from the library pool, an increasing amount of ssDNA bound to
target-coated magnetic beads after each round of selection (Fig. 1).
The aptamers were subsequently cloned, and 50 clones were
analyzed for further characterization. Among these clones, one
apatmer termed MA3 showed relatively high binding to the target
MUC1 peptides. The DNA sequence of the aptamer MA3 is
59AACCGCCCAAATCCCTAAGAGTCGGACTGCAACCT-
ATGCTATCGTTGATGTCTGTCCAAGCAACACAGACACA-
CTACACACGCACA39.
Binding specificity is important for evaluation of aptamer
performance. Since albumin is the most abundant protein in
blood, we examined the binding of the aptamer MA3 to albumin.
Albumin or MUC1 peptides coated beads were incubated with
FITC-labeled MA3, and analyzed by flow cytometry. Unselected
Figure 1. Flow cytometry monitoring of the enrichment of
aptamers. Compared with the starting random DNA pool (shaded
histogram), flow cytometry revealed an increase in fluorescence
intensity of aptamers bound to the MUC1 peptide (APDTRPAPG) after
the third (the gray curve) and forth (the black curve) rounds of
selection.
doi:10.1371/journal.pone.0031970.g001
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presented in Figure 2, the MA3 aptamer generated a significant
binding to MUC1 peptides (Fig. 2A), but a relatively weak binding
to BSA similar to that generated by random DNA (Fig. 2B). The
results suggested that, between the MUC1 peptides and albumin,
the aptamer MA3 exhibited a targeting specificity towards the
former. As a comparison, similar experiments were conducted for
another MUC1 aptamer, S2.2, which had the lowest Kd among all
the published MUC1 aptamers [15,16]. The results showed that
while S2.2 could bind to MUC1 peptides (Fig. 2C), it also bound
to albumin to a certain degree (Fig. 2D). The data indicated that,
compared to S2.2, MA3 had a lower cross reactivity to albumin.
To quantitatively evaluate the binding affinity of the aptamer to
MUC1, beads coated with MUC1 peptides were incubated with
FITC-labeled MA3 of various concentrations (Fig. 3A). Using
non-linear regression analysis, the aptamer was found to have a Kd
of 38.3 nM. To further evaluate whether the aptamer MA3 would
bind to MUC1 structure, we also examined its binding to a 29-AA
peptides (GSTAPPAGHGVTSAPDTRPAPGPGSTAPP) con-
taining the entire tandem repeat sequence (TAPPAGHGVT-
SAPDTRPAPGPGS) that made up the extracellular MUC1
protein core. The 29-AA peptides were covalently conjugated to
magnetic beads, which were incubated with FITC-labeled MA3
and analyzed by flow cytometry. FITC-labeled random DNA
from the library pool was used as control. As shown in Fig. 3B,
MA3 generated a fluorescence signal that was significantly more
potent than random DNA, indicating that the aptamer could also
bind to a structure containing the entire MUC1 tandem repeat
sequence. Since the extracellular domain of MUC1 protein core is
primarily made of the tandem repeats, it is possible that the
aptamer MA3 may recognize the MUC1 structure exposed on the
surface of MUC1-expressing tumor cells.
MA3 aptamer selectively binds to MUC1-expressing
tumor cells
To evaluate whether the aptamer MA3 would bind to MUC1-
expressing cancer cells, FITC-labeled MA3 was incubated with
either the MUC1-positive (A549 or MCF7) [21,22] or the MUC1-
negative (HepG2 or L02) cell lines [21,23]. The cells were later
analyzed by flow cytometry, using the cells incubated with FITC-
Figure 2. Flow cytometry assessment of the bindings to MUC1-peptide or BSA by FITC-labeled aptamers MA3 and S2.2. (A) MUC1-
peptide beads treated with MA3. (B) BSA beads treated with MA3. (C) MUC1-peptide beads treated with S2.2. (D) BSA beads treated with S2.2. The
filled histograms represent the control fluorescent signals generated by FITC-labeled random DNA from the library pool.
doi:10.1371/journal.pone.0031970.g002
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presented in Figure 4. For MUC1-positive cell lines A549 and
MCF7, MA3 treatment generated fluorescence signals that were
significantly more potent than that of random DNA treatment
(Fig. 4A and B). However, for MUC1-negative cell lines HepG2
and L02, MA3 treatment resulted in fluorescence signals that were
Figure 3. Evaluation of MA3’s affinity to MUC1 structures. (A) Quantitative assay of the affinity between FITC-labeled MA3 and the MUC1
epitope (APDTRPAPG). (B) Flow cytometry analysis of binding between FITC-labeled MA3 and the 26-AA MUC1 peptide (GSTAPPAGHGVTSAPDTR-
PAPGPGSTAPP). The filled histogram is the control fluorescence background generated by FITC-labeled random DNA from the library pool.
doi:10.1371/journal.pone.0031970.g003
Figure 4. Flow cytometry evaluation of MA3’s binding to MUC1-positive and -negative cells. The histograms were generated after
incubating FITC-labeled MA3 with A549 (A), MCF7 (B), HepG2 (C), and L02 (D) cells, respectively. The filled histograms represent the control
fluorescence signals generated by FITC-labeled random DNA from the library pool.
doi:10.1371/journal.pone.0031970.g004
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results indicated that the aptamer MA3 could preferentially bind
to MUC1-positive cancer cells, and that the aptamer might
recognize the MUC1 structure on these cells.
MUC1 expression influences the binding of the aptamer
to tumor cells
To further investigate the binding of the aptamer to MUC1-
positive tumor cells, the expression of MUC1 protein in A549 and
HepG2 cells were evaluated by western blot with anti-MUC1
antibody. As presented in Figure 5A, while A549 cells expressed
MUC1 protein in ample amount, HepG2 cells did not, suggesting
that A549 was indeed a MUC1-positive cell line and that HepG2
was a MUC1-negative cell line. The results are in agreement with
multiple published studies, which extensively analyzed the expres-
sion of the MUC1 in various cell lines and clearly identified A549 as
MUC1-positive and HepG2 as MUC1-negative cell line [18,24].
To evaluate the influence of MUC1 expression on the aptamer’s
binding to MUC1-positive cells, we utilized MUC1 siRNA that
had been previously shown capable of knocking down the MUC1
expression [18]. The siRNA was transfected into the MUC1-
positive A549 cells, and was confirmed with western blot that it
could down regulate the MUC1 expression (Fig. 5A). A549 cells
were treated with either MUC1 siRNA or a control siRNA,
incubated with FITC-labeled aptamer, and evaluated by flow
cytometry. As presented in Figure 5B and C, the aptamer binding
to the cells was significantly reduced after down-regulation of
MUC1 expression (Fig. 5B), whereas the binding to cells treated
with control siRNA were not affected (Fig. 5C). The results
suggested that MUC1 expression on target cells influenced the
aptamer’s affinity to these cells, and that the loss of MUC1 protein
could reduce the aptamer binding significantly.
Loading the aptamer with Dox
In order to deliver Dox to MUC1-positive tumor cells, an
aptamer-doxorubicin complex (Apt-Dox) was formed by interca-
lating doxorubicin into the DNA structure of the MA3 aptamer.
To evaluate whether Dox was indeed incorporated into MA3, we
made use of the phenomenon that the fluorescence from Dox
would be quenched after intercalating into DNA [25]. Specifically,
we carried out binding studies between MA3 and Dox, and
employed fluorescence spectroscopy to assess the fluorescent signal
generated by doxorubicin. As shown in Figure 6A, sequential
decreases in the native fluorescence spectrum of Dox were
observed when a fixed concentration of Dox was incubated with
an increasing molar ratio of the MA3 aptamer. When the
aptamer/dox molar ratio reached 0.1, the fluorescence spectrum
of Dox was at the lowest level and did not change further,
indicating that most dox had incorporated into the DNA structure
of MA3 at this aptamer/dox ratio.
To investigate whether the intercalation of doxorubicin into
aptamer would interfere with the aptamer’s affinity to MUC1-
positive tumor cells, the binding of Apt-Dox complex to A549 cells
was evaluated with flow cytometry, and compared with that of
MUC1 aptamer alone. As shown in Figure 6B and C, Apt-Dox
complex (Fig. 6C) had an affinity to A549 cells that was similar to
MUC1 aptamer alone (Fig. 6B). The results suggested that
intercalation of doxorubicin into MUC1 aptamer did not
significantly interfere with the binding of the aptamer to MUC1-
positive tumor cells.
Figure 5. Western blot of MUC1 protein and siRNA interference experiments. (A) Western blots of protein extracts from A549 cells, HepG2
cells, A549 cells treated with control siRNA, and A549 cells treated with MUC1 siRNA, respectively. Actin was also blotted to serve as the control. (B
and C) Flow cytometry evaluation of the apatamer’s binding to A549 cells treated with MUC1 siRNA (B) or control siRNA (C). The filled histograms
represent the control fluorescence signals generated by FITC-labeled random DNA from the library pool.
doi:10.1371/journal.pone.0031970.g005
MUC1 Aptamer Delivers Cytotoxic Agent In Vitro
PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e31970Aptamers as vehicles for selective delivery of doxorubicin
to MUC1 positive cancer cells
The nonselective uptake of free Dox by both cancer and normal
cells is a primary cause for its adverse effects against normal tissue.
When Dox is intercalated into the DNA structure of the MUC1
aptamer (Apt-Dox), the complex may preferentially bind to MUC1-
positive cancer cells. To test this postulate, the fluorescence
properties of doxorubicin were utilized to evaluate the drug uptake
by either MUC1-positive (A549) or MUC1-negative (HepG2) cells.
The cells were incubated separately with free Dox or Apt-Dox and
analyzed by confocal microscopy. The results showed that the red
fluorescence from the drug was equally strong in the two cell lines
treated with free Dox (Fig. 7A and B), indicating that the uptake of
free Dox by these cells was non-selective. In contrast, when the cells
were treated with Apt-Dox, the fluorescence in MUC1-positive
A549 cells was significantly higher than that in MUC1-negative
HepG2 cells (Fig. 7C and D), and that the uptake of the drug by
HepG2 cells was markedly decreased. The results suggested that
Apt-Dox exhibited cell-specificity and could be selectively taken up
by MUC1-positive cells. Interestingly, the intracellular distribution
of the drug in A549 cells was mainly limited to the nuclei with free
Dox, but extended to cytoplasm in the setting of Apt-Dox,
suggesting that the mechanisms for uptake of free Dox and Apt-
Dox might be different.
To further study whether Apt-Dox could be selectively taken up
by MUC1 positive cells, flow cytometry was also employed to
monitor the fluorescence generated by doxorubicin after incubating
the two cell lines with free Dox or Apt-Dox. For MUC1-positive
A549cells,thefluorescentsignalsgeneratedbyfree DoxorApt-Dox
were similar (Fig. 7E); whereas for MUC1-negative HepG2 cells,
the fluorescent signal generated by Apt-Dox was remarkably lower
than that generated by free Dox (Fig. 7F). The results again
suggested that Apt-Dox could be selectively taken up by MUC1
positive cancer cells. Taken together, our microscopy and flow
cytometry data indicate that the aptamer MA3 may serve as a
vehicle for targeted delivery of Dox to MUC1-positive cancer cells.
Apt-Dox selectively reduced cytotoxicity to MUC1-
negative cancer cells
Since the uptake of doxorubicin was reduced in MUC1-
negative cells treated with Apt-Dox, it is possible that the
cytotoxicity to these cells would also be decreased. To test the
postulate, in vitro cytotoxicity caused by Apt-Dox or free Dox was
compared in HepG2 and A549 cell lines. As presented in
Figure 8A, for MUC1-negative HepG2 cells, the cytotoxicity
generated by Apt-Dox was indeed decreased compared to that
generated by free Dox (P,0.01). However, for MUC1-positive
A549 cells, no difference was detected between the cytotoxicity
generated by Apt-Dox or free Dox (Fig. 8B). The results suggest
that Apt-Dox tends to reduce the damage to MUC1-negative cells
while retaining the efficacy of the doxorubicin against MUC1-
positive cells. It should be noted that aptamer alone was nontoxic
Figure 6. Fluorescence spectra of Apt-Dox and flow cytometry evaluation of Apt-Dox’s binding to A549 cells. (A) Fluorescence spectra
of doxorubicin solution mixed with increasing molar ratios of the MA3 aptamer (from top to bottom: 0, 0.001, 0.003, 0.005, 0.01, 0.03, 0.1, and 1). (B)
A549 cells treated with FITC-labeled MA3 aptamer. (C) A549 cells treated with FITC-labeled Apt-Dox. The filled histograms represent the control
fluorescence signals generated by FITC-labeled random DNA from the library pool.
doi:10.1371/journal.pone.0031970.g006
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relatively safe to the cells and that the cytotoxicity was mainly
caused by doxorubicin.
Discussion
The efficacy of chemotherapy is often limited by the adverse
effects of cytotoxic agents that damage both cancer and normal
cells. One strategy for reducing the adverse effects of chemother-
apy is targeted drug delivery to cancer cells. MUC1 is considered a
valuable target for ligand-guided anticancer chemotherapy due to
its over-expression in most adenocarcinomas. Here in this study,
using the SELEX technique and a peptide epitope of MUC1 as
target, we developed a novel MUC1 aptamer (MA3) with a Kd of
38.3 nM. We found that MA3 could specifically bind to MUC1-
positive cancer cells, with minimal cross reactivity to albumin
(Fig. 1,2,3,4). Moreover, an aptamer-drug complex (Apt-Dox) was
formed by intercalating doxorubicin into the DNA structure of the
MA3 aptamer (Fig. 6). Importantly, Apt-Dox resulted in a selective
uptake of doxorubicin into MUC1-positive cells while significantly
reduced the drug intake by MUC1-negative cells (Fig. 7). In
addition, Apt-Dox retained the efficacy of doxorubicin against
MUC1-positive cells, while notably lowered the toxicity to MUC1-
negative cells (Fig. 8). The results suggested that Apt-Dox could
discriminate between target and non-target cells.
The extracellular domain of MUC1 is a glycoprotein consisting
of a protein core and O-linked oligosaccharides [19]. The protein
core contains variable number of a tandem repeat sequence
Figure 7. Uptake of doxorubicin by MUC1-positive (A549) and -negative (HepG2) cells. (A–D) Confocal laser scanning microscopy images
of A549 and HepG2 cells after incubation with free doxorubicin (A and B) or Apt-Dox (C and D) for 2 hours. (E and F) Flow cytometry histogram
profiles of A549 (E) and HepG2 cells (F) after incubation with either free doxorubicin (black curves) or Apt-Dox (gray curves). The filled histograms are
the control signals generated by untreated cells.
doi:10.1371/journal.pone.0031970.g007
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PAPGPGS). In normal tissue, the protein core of MUC1 is
usually shielded by the saccharide chains; whereas in tumor cells,
the protein core is exposed due to deficient glycosylation, allowing
the tandem repeat sequences to serve as potential target for
anticancer therapy [26]. In this study, a 9-AA peptides
(APDTRPAPG) within the MUC1 tandem repeat sequence was
employed as the target for aptamer selection, because it was
identified as the most immunodominant peptide epitope within the
protein core. MUC1 aptamers reported in previous studies was
also selected using this epitope as target, presumably because the
complete MUC1 protein core was difficult to obtain technically.
The MUC1 aptamer MA3 developed in this study not only bound
to the 9-AA MUC1 peptide epitope (Fig. 2A), but also recognized
a 29-AA peptides (GSTAPPAGHGVTSAPDTRPAPGPG-
STAPP) containing the entire MUC1 tandem repeat sequence
(Fig. 3B). Moreover, MA3 exhibited potent binding to MUC1-
positive cells A549 and MCF7, but relatively weak binding to
MUC1-negative cells HepG2 and L02 (Fig. 4). The results suggest
that MA3 may selectively recognize the MUC1 structure
expressed on the surface of MUC1-expressing cancer cells.
In order for the aptamer to serve as targeting ligand, it needs to
bind to MUC1 structure with certain specificity. In other words,
the nonspecific binding to other proteins by the aptamer should be
kept at minimum. Since albumin is the most abundant protein in
blood, we evaluated the binding of albumin to MA3 and another
MUC1 aptamer, S2.2, which had the highest targeting affinity
among all the MUC1 aptamers reported in literature. While both
MA3 and S2.2 bound to MUC1 with good affinity, the MA3’s
binding to albumin was significantly lower than that of S2.2
(Fig. 2). The data indicate that MA3 has a more selective binding
to MUC1 with less nonspecific binding to albumin compared to
S2.2, presumably because that the relatively larger size of MA3
(86-base for MA3 vs. 25-base for S2.2) potentially permits more
complexity in its binding function, and that albumin was present in
the buffer during the selection of MA3. Nevertheless, the in vivo
MA3 binding specificity for MUC1 still needs to be evaluated with
extensive future animal studies.
In this study, the uptake of doxorubicin by different cell lines
was evaluated by confocal microscopy and flow cytometry. Free
doxorubicin showed no preferential internalization in either
MUC1-positive or MUC1-negative cells, presumably because
the mechanism of uptake for free drug is similar for both cell lines
(Fig. 7A and B). In contrast, Apt-Dox generated a doxorubicin
fluorescence that was distinctively more potent in MUC1-positive
cells as compared with that in MUC1-negative cells (Fig. 7C and
D, 6E and F). This is a strong indication that Apt-Dox can
discriminate efficiently between target and non-target cells.
The mechanisms of uptake of free Dox and Apt-Dox by cells
appear distinct. Unlike free Dox, which exclusively stained the
nuclei (Fig. 7A), Apt-Dox generated both nuclear and cytosolic
staining (Fig. 7C). While free doxorubicin could non-selectively
enter cells via passive diffusion, the polar components of the DNA
aptamer presumably would prevent the doxorubicin intercalated
in Apt-Dox from freely defusing into the lipid cell membrane. It
was possible that Apt-Dox entered MUC1-positive cells via
receptor-mediated endocytosis [27], which occurred after Apt-
Dox bound to the MUC1 structure on A549 cell surface. Less
entry of doxorubicin into HepG2 cells might come from lack of
aptamer binding site on these MUC1-negative cells. As a result, a
distinction in doxorubicin uptake between MUC1-positive and
MUC1-negative cells was created. The cytotoxicity assay also
supported the doxorubicin uptake data. For MUC1-positive cells,
the cytotoxicity generated by Apt-Dox was similar to that
generated by free doxorubicin; whereas for MUC1-negative cells,
the cytotoxicity generated by Apt-Dox was reduced compared to
that caused by free doxorubicin (Fig. 8, P,0.01). The data again
suggested that the Apt-Dox could selectively deliver drug to
MUC1-positive cancer cells. This presumably would decrease the
adverse effects of doxorubicin against normal tissues that are
largely MUC1-negative.
Many published studies on aptamer-guided targeted therapy
employed nanoparticle (NP) as the carrier of anticancer agents
[11,28,29]. However, it has also been reported that aptamer alone,
without the carrier vehicle, could effectively deliver siRNA to
tumor cells in vivo [30]. It would be interesting to know whether
aptamer alone could also be employed for delivery of cytotoxic
drugs (such as doxorubicin) to tumor cells. To achieve this goal,
the drug needs to be associated with the aptamer, and the method
for forming the aptamer-drug complex would probably influence
the therapeutic efficacy. It is possible that covalent conjugation of
doxorubicin to the tumor-targeting ligand may decrease the drug
efficacy, presumably by altering the drug structure or by
compromising the drug release from the targeting ligand [31].
Here in this study, the doxorubicin was not covalently conjugated
to the aptamer, allowing the drug to be released more readily from
Figure 8. Cell viability assays after the cells were treated with aptamer, free Dox, or Apt-Dox for 4 hours. The HepG2 (A) and A549 (B)
cells were evaluated with a standard MTS assay after 48 h of further incubation (mean6SD, n=6).
doi:10.1371/journal.pone.0031970.g008
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complex is unknown at this stage, and extensive future research
with in vivo animal studies is necessary to evaluate the stability of
Apt-Dox in blood and tissues.
In summary, a novel MUC1 aptamer MA3 is developed in this
study. The Apt-Dox complex could selectively deliver the cytotoxic
agent doxorubicin to MUC1-positive cells, while reducing the
drug uptake by MUC1-negative cells. Since MUC1 is over-
expressed in most adenocarcinomas, the aptamer may have
potential utility as a guiding ligand for targeted chemotherapy
against these malignancies. Nevertheless, extensive future research
with animal models is still needed to evaluate the in vivo binding
specificity of the aptamer. In addition, it is also necessary to
explore optimal ways to generate the aptamer-drug complex for
most efficient in vivo delivery of cytotoxic anticancer agents to
cancer cells.
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